Asthma and COVID-19

Abstract

Pandemic of COVID-19 which has recently influenced our country and the global world, has been an important public health problem. It is possible that patients with asthma may also be affected in this outbreak. At this stage, the correct approach of physicians to patients with asthma can be achieved by revealing the relationship between asthma and COVID-19. Up to now, it has been reported that COVID-19 controlled asthma does not pose an additional risk for controlled asthma COVID-19. However, it is still important to ensure that patients with asthma follow social isolation and personal hygiene rules. Treating asthma according to current guidelines is an appropriate approach, until new information is available.

Keywords

• Asthma
• COVID-19
• SARS-CoV-2

Astım ve COVID-19

Abstract

Son günlerde ülkemiz ve tüm dünyayı etkisi altına alan COVID-19 pandemisi önemli bir halk sağlığı sorunu olmuştur. Salgında astımlı hastaların da etkilenmesi mümkündür. Bu aşamada hekimlerin astımlı hastalara doğru yaklaşımı astım COVID-19 arasındaki ilişkinin ortaya konması ile sağlanabilir. Şu ana kadar kontol altındaki astımlılar için COVID-19’un için ek risk getirmediği oluşturmadığı bildirilmişti. Ancak yine de astım hastalarının sosyal izolasyon ve kişisel hijyen kurallarına uymalarının sağlanması önemlidir. Yeni bilgiler elde edilinceye kadar astımın mevcut rehberlere göre tedavi edilmesi uygun bir yaklaşımdır.

Keywords

• Astım
• COVID-19
• SARS-CoV-2

References

1. 1. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü COVID-19 (SARSCoV- 2 Enfeksiyonu) Rehberi. Erişim: https://covid19bilgi.saglik.gov. tr/depo/rehberler/COVID19. Son erişim tarihi: 14.04.2020.
2. 2. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/dg/speeches/ detail/who-director-general-s-opening-remarks-at-the-mediabriefing- on-covid-19---11-march-2020
3. 3. COVID-19 Durum Raporu. https://covid19.saglik.gov.tr/TR-68443/ covid-19-durum-raporu.html. 5.4.2020
4. 4. Lupia T, Scabini S, Pinna SM, Di Perri G, De Rosa FC, Corcione S. 2019-novel Coronavirus Outbreak: A New Challenge. J Glob Antimicrob Resist 2020 Jun;21:22-27. doi: 10.1016/j. jgar.2020.02.021. Epub 2020 Mar 7. PMID: 32156648; PMCID: PMC7102618.
5. 5. Onder G, Rezza G, Brusaffero S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020 May 12;323(18):1775-1776. doi: 10.1001/jama.2020.4683. Erratum in: JAMA. 2020 Apr 28;323(16):1619. PMID: 32203977.
6. 6. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis, Int J Infect Dis 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12. PMID: 32173574; PMCID: PMC7194638.
7. 7. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ 2020 Mar 26;368:m1198. doi: 10.1136/ bmj.m1198. PMID: 32217618.
8. 8. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020 Mar 18;24(1):108. doi: 10.1186/s13054-020-2833-7. PMID: 32188484; PMCID: PMC7081524.

9. 9. Richardson S, Hirsh JS, Narasimhan M, Crawford JM, Mc Ginn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020 May 26;323(20):2052- 2059. doi: 10.1001/jama.2020.6775. Erratum in: doi: 10.1001/ jama.2020.7681. PMID: 32320003; PMCID: PMC7177629.
10. 10. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020 Jun;109(6):1088-1095. doi: 10.1111/apa.15270. Epub 2020 Apr 14. PMID: 32202343; PMCID: PMC7228328.
11. 11. Sun D, Li H, Lu X, Xiao X, Xiao H, Ren J, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World J Pediatr 2020 Jun;16(3):251-259. doi: 10.1007/s12519-020-00354-4. Epub 2020 Mar 19. PMID: 32193831; PMCID: PMC7091225.
12. 12. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27. PMID: 32077115.
13. 13. Dong X, Cao Y, Lu X, Zhang J, Du H, Yan Y, et al. Eleven faces of coronavirus disease 19. Allergy 2020 Jul;75(7):1699-1709. doi: 10.1111/all.14289. Epub 2020 Apr 6. PMID: 32196678; PMCID: PMC7228397.
14. 14. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28. PMID: 32109013; PMCID: PMC7092819.
15. 15. AAAAI: Asthma and COVID-19 Update. Erişim: https:// contentsharing.net/actions/email_web_version.cfm?recipient_ id=3712797199&message_id=18453579&user_id=AAAAI&group_ id=0&jobid=47601295. Son erişim tarihi: Eylül 2020.
16. 16. CDC: Coronavirus Disease 2019 (COVID-19): People Who Are At High Risk. Erişim: https://www.cdc.gov/coronavirus/2019-ncov/ need-extra-precautions/asthma.html. Son erişim tarihi: Eylül 2020.
17. 17. Abrams EM, Szefler SJ. Managing Asthma during Coronavirus Disease-2019: An Example for Other Chronic Conditions in Children and Adolescents. J Pediatr 2020 Jul;222:221-226. doi: 10.1016/j. jpeds.2020.04.049. Epub 2020 Apr 21. PMID: 32330469; PMCID: PMC7172836.
18. 18. Shaker MS, Oppenheimer J, Grayson M, Stukus D, Hartog N, Hsieh EWY, et al. COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic. J Allergy Clin Immunol Pract 2020 May;8(5):1477-1488.e5. doi: 10.1016/j.jaip.2020.03.012. Epub 2020 Mar 26. PMID: 32224232; PMCID: PMC7195089.
19. 19. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317- 2. Epub 2020 Feb 7. PMID: 32043983; PMCID: PMC7134694.
20. 20. Sahng L, Zhao L, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020 Feb 29;395(10225):683-684. doi: 10.1016/S0140-6736(20)30361-5. Epub 2020 Feb 12. PMID: 32122468; PMCID: PMC7159292.
21. 21. Global Initiative for Asthma (GINA) 2020. Interim guidance on asthma management during the COVID-19 pandemic. Erişim: https://ginasthma.org/gina-reports/. Son erişim tarihi: 29.04.2020.
22. 22. Lazzeri M, Lanza A, Bellini R, Bellafiore A, Cecchetto S, Colombo A, et al. Respiratory physiotherapy in patients with COVID-19 infection in acute settings: a Position Paper of the Italian Association of Respiratory Physiotherapists (ARIR). Monaldi Arch Chest Dis 2020 Mar 26;90(1). doi: 10.4081/monaldi.2020.1285. PMID: 32236089.
23. 23. Simonds AK, Hanak A, Chatwin M, Morrell M, Hall A, Parker KH, et al. Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. Health Technol Assess 2010 Oct;14(46):131-172. doi: 10.3310/hta14460-02. PMID: 20923611.
24. 24. Zhonghua Jie He He Hu Xi Za Zhi. Respiratory Care Committee of Chinese Thoracic Society. Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia. 2020 Apr 12;43(4):288-296. Chinese. doi: 10.3760/cma.j.cn11214 7-20200304-00239. PMID: 32294813.
25. 25. Amitrav I. Newhause MT. Transmission of coronavirus by nebulizer: a serious, underappreciated risk. CMAJ 2020 Mar 30;192(13):E346. doi: 10.1503/cmaj.75066. PMID: 32392488; PMCID: PMC7124163.
26. 26. Judson SD, Munster VJ. Nosocomial transmission of emerging viruses via aerosol-generating medical procedures. Viruses 2019 Oct 12;11(10):940. doi: 10.3390/v11100940. PMID: 31614743; PMCID: PMC6832307.
27. 27. Türkiye Acil Tıp Derneği COVİD 19 Havayolu Yönetimi Önerileri https://tatd.org.tr/uploads/files/COVID19%20Havayolu%20 Yo%CC%88netimi%20O%CC%88nerileri.pdf
28. 28. Bough HA, Kalaycı O, Sediva A, Untersmayr E, Munblit D, Del Rio PR, et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – the 2020 COVID-19 pandemic A statement from the EAACI-Section on pediatrics. Pediatr Allergy Immunol 2020 Apr 22:10.1111/pai.13262. doi: 10.1111/pai.13262. Epub ahead of print. PMID: 32319129; PMCID: PMC7264548.
29. 29. Editorial Lancet. COVID-19: Protecting Health-Care Workers. Lancet 2020,doi: 10.1016/s10140-6736(20)30644-9.
30. 30. Webber CM, Calabria CW. Assessing the safety of subcutaneous immunotherapy dose adjustments. Ann Allergy Asthma Immunol. 2010;105:369-375.
31. 31. Klimek L, Jutel M, Akdis C, Bosquet J, Akdis M, Bachert C, et al. Handling of allergen immunotherapy in the COVID-19 pandemic; an ARIA-EAACI statement. Doi:10.1111/ALL.14336.